20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- The FDA has granted Orphan Drug designation to Kiora Pharmaceuticals Inc's (NASDAQ:KPRX) KIO-301 for Retinitis Pigmentosa.
- Retinitis Pigmentosa is an inherited genetic eye disease that can lead to severe vision loss due to rods and cones degeneration.
- Kiora expects to initiate clinical trials of KIO-301 in Q3 2022.
- The Company plans to begin a Phase 1b clinical trial in Australia later this year before initiating more extensive studies in the U.S. and worldwide.
- KIO-301 (benzyl ethyl aminoazobenzene quaternary ammonium) is a visible light-sensitive small molecule that acts as a reversible 'photoswitch,' specifically designed to restore the eyes' ability to perceive and interpret light in visually impaired patients.
- Price Action: KPRX shares are down 10.4% at $0.70 during the market session on the last check Friday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!